SCHEMBL6477384

SCHEMBL6477384

O=C(O)c1cccc(SCCCc2ccccc2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APEX1 P27695 1/20 0.58
CYP1A2 P05177 1/20 0.53
CYP2C9 P11712 1/20 0.53
HPGD P15428 1/20 0.53
HSD17B10 Q99714 1/20 0.53
PLA2G2A P14555 1/20 0.51
MCL1 Q07820 2/20 0.50
BCL2A1 Q16548 2/20 0.50
PLA2G4B P0C869 2/20 0.50
PLA2G4A P47712 1/20 0.50
HDAC1 Q13547 1/20 0.48
NR1H4 Q96RI1 1/20 0.47
RAB9A P51151 2/20 0.46
ALDH1A1 P00352 1/20 0.46
NPC1 O15118 1/20 0.46
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6477192 0.92 APEX1 (0.63) APEX1CYP1A2CYP2C9HPGDHSD17B10
SCHEMBL28104567 0.91 PLA2G2A (0.51) APEX1CYP1A2CYP2C9HPGDHSD17B10
SCHEMBL6484061 0.83 PLA2G2A (0.69) PLA2G2AMCL1BCL2A1PLA2G4BPLA2G4A
SCHEMBL5315791 0.81 APEX1 (0.61) APEX1CYP1A2CYP2C9HPGDHSD17B10
SCHEMBL30198674 0.81 APEX1 (0.65) APEX1CYP1A2CYP2C9HPGDHSD17B10
SCHEMBL3889076 0.81 APEX1 (0.65) APEX1CYP1A2CYP2C9HPGDHSD17B10
SCHEMBL11725367 0.80 HDAC1 (0.52) APEX1CYP1A2CYP2C9HPGDMCL1
SCHEMBL16344775 0.79 APEX1 (0.67) APEX1CYP1A2CYP2C9HPGDHSD17B10
SCHEMBL6489146 0.79 APEX1 (0.58) APEX1CYP1A2CYP2C9HPGDHSD17B10
SCHEMBL7814196 0.79 APEX1 (0.58) APEX1CYP1A2CYP2C9HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887863-B2 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES (US) 2005-05-03 US disclosed
EP-1272456-B1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LAB (US) 2004-10-27 EP disclosed
US-20040167126-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBVIE INC. 2004-08-26 US disclosed
EP-1272456-A1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS Abbott Laboratories (US) 2003-01-08 EP disclosed
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES 2002-01-03 US disclosed
WO-2001079157-A1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167126-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP APEX1 1768/4885CYP1A2 1673/4885CYP2C9 2947/4885
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP APEX1 1768/4885CYP1A2 1673/4885CYP2C9 2947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.